PORTOLA VALLEY, Calif.
, Nov. 2, 2010
/PRNewswire/ -- Spectros Corporation presented new clinical results using tissue oxygen saturation with the T-Stat VLS Tissue Oximeter at the San Diego
Convention Center during Anesthesiology 2010. This newly released data was presented during poster sessions entitled "Experimental Circulation: Ischemia and Reperfusion" and "Clinical Circulation: Pharmacology/Physiology", held at the American Society of Anesthesiologists (ASA 2010) on October 16, 2010
in San Diego, CA.
The studies were both conducted at Loma Linda University
Medical Center in Loma Linda, CA.
Loma Linda is just one of the newest locations across the US who is relying on the T-Stat to improve the standard of care and help cut costs. The abstracts, titled, "Regional Tissue Oxygen Saturation in an Animal Model of Global and Regional Oxygen Delivery Insults" and "Esophageal and Buccal Mucosal Oxygen Saturation in Patients Undergoing Cardio-Pulmonary Bypass," help with the ability to assess oxygen delivery to an organ system to provide a more sensitive mode to detect critical disease.
The T-Stat VLS technology can be easily used to monitor the tissue oxygen saturation in numerous locations in the body with a selection of sensors. This concept of monitoring tissue perfusion is not new to the market, however T-Stat's successful and patented VLS white light technology is.
New findings within modern medicine are requiring more modern technologies to assist in tougher diagnosis and more challenging cases. The T-Stat fills this need with the ability to respond within seconds to changes in tissue perfusion, allowing for real time management of fluid status, cardiac output, and impending shock during surgery, post-operatively, and in the ICU. "Doctors continue to be enthusiastic about T-Stat's superior performance when compared directly to other tissue oximetry products. We are pleased that T-Stat is gaining momentum in Anesthesiology research and practice," noted Elizabeth van Thillo, Director of Marketing.
Along with the many Anesthesiologists across the US, Spectros is becoming a joining force in improving patient care and making sure that doctors can offer and maintain a safe and successful surgical experience.
Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology. The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.
Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only. T-Stat and Continuum are trademarks of the Spectros Corporation.).
For further information, visit www.spectros.com.